Literature DB >> 20705614

Patterns of expression of DNA repair genes and relapse from melanoma.

Rosalyn Jewell1, Caroline Conway, Angana Mitra, Juliette Randerson-Moor, Samira Lobo, Jérémie Nsengimana, Mark Harland, Maria Marples, Sara Edward, Martin Cook, Barry Powell, Andy Boon, Floor de Kort, Katharine A Parker, Ian A Cree, Jennifer H Barrett, Margaret A Knowles, D Timothy Bishop, Julia Newton-Bishop.   

Abstract

PURPOSE: To use gene expression profiling of formalin-fixed primary melanoma samples to detect expression patterns that are predictive of relapse and response to chemotherapy. EXPERIMENTAL
DESIGN: Gene expression profiles were identified in samples from two studies (472 tumors). Gene expression data for 502 cancer-related genes from these studies were combined for analysis.
RESULTS: Increased expression of DNA repair genes most strongly predicted relapse and was associated with thicker tumors. Increased expression of RAD51 was the most predictive of relapse-free survival in unadjusted analysis (hazard ratio, 2.98; P = 8.80 × 10(-6)). RAD52 (hazard ratio, 4.73; P = 0.0004) and TOP2A (hazard ratio, 3.06; P = 0.009) were independent predictors of relapse-free survival in multivariable analysis. These associations persisted when the analysis was further adjusted for demographic and histologic features of prognostic importance (RAD52 P = 0.01; TOP2A P = 0.02). Using principal component analysis, expression of DNA repair genes was summarized into one variable. Genes whose expression correlated with this variable were predominantly associated with the cell cycle and DNA repair. In 42 patients treated with chemotherapy, DNA repair gene expression was greater in tumors from patients who progressed on treatment. Further data supportive of a role for increased expression of DNA repair genes as predictive biomarkers are reported, which were generated using multiplex PCR.
CONCLUSIONS: Overexpression of DNA repair genes (predominantly those involved in double-strand break repair) was associated with relapse. These data support the hypothesis that melanoma progression requires maintenance of genetic stability and give insight into mechanisms of melanoma drug resistance and potential therapies. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705614      PMCID: PMC2972254          DOI: 10.1158/1078-0432.CCR-10-1521

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Chemotherapy for metastatic melanoma: time for a change?

Authors:  Helen J Gogas; John M Kirkwood; Vernon K Sondak
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

3.  The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Authors:  Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta
Journal:  BMC Med Genomics       Date:  2008-04-28       Impact factor: 3.063

4.  Individualized prognosis for melanoma patients.

Authors:  A J Cochran; D Elashoff; D L Morton; R Elashoff
Journal:  Hum Pathol       Date:  2000-03       Impact factor: 3.466

5.  High expression of DNA repair pathways is associated with metastasis in melanoma patients.

Authors:  A Kauffmann; F Rosselli; V Lazar; V Winnepenninckx; A Mansuet-Lupo; P Dessen; J J van den Oord; A Spatz; A Sarasin
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

Review 6.  Overexpression of DNA repair genes is associated with metastasis: a new hypothesis.

Authors:  Alain Sarasin; Audrey Kauffmann
Journal:  Mutat Res       Date:  2008-01-16       Impact factor: 2.433

Review 7.  O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

Authors:  Barbara Verbeek; Thomas D Southgate; David E Gilham; Geoffrey P Margison
Journal:  Br Med Bull       Date:  2008-02-01       Impact factor: 4.291

Review 8.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

9.  TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.

Authors:  Nathalie Wong; Winnie Yeo; Wai-Lap Wong; Navy L-Y Wong; Kathy Y-Y Chan; Frankie K-F Mo; Jane Koh; Stephan Lam Chan; Anthony T-C Chan; Paul B-S Lai; Arthur K-K Ching; Joanna H-M Tong; Ho-Keung Ng; Philip J Johnson; Ka-Fai To
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

10.  A new non-linear normalization method for reducing variability in DNA microarray experiments.

Authors:  Christopher Workman; Lars Juhl Jensen; Hanne Jarmer; Randy Berka; Laurent Gautier; Henrik Bjørn Nielser; Hans-Henrik Saxild; Claus Nielsen; Søren Brunak; Steen Knudsen
Journal:  Genome Biol       Date:  2002-08-30       Impact factor: 13.583

View more
  31 in total

1.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Advances in molecular profiling of malignant melanoma: ready for clinical practice?

Authors:  Göran Jönsson
Journal:  Melanoma Manag       Date:  2014-09-05

3.  Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma.

Authors:  Joanna Poźniak; Jérémie Nsengimana; Jonathan P Laye; Sally J O'Shea; Joey Mark S Diaz; Alastair P Droop; Anastasia Filia; Mark Harland; John R Davies; Tracey Mell; Juliette A Randerson-Moor; Sathya Muralidhar; Sabrina A Hogan; Sandra Nicole Freiberger; Mitchell P Levesque; Graham P Cook; D Timothy Bishop; Julia Newton-Bishop
Journal:  Cancer Res       Date:  2019-02-17       Impact factor: 12.701

4.  Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

Authors:  Arvind Arora; Swetha Parvathaneni; Mohammed A Aleskandarany; Devika Agarwal; Reem Ali; Tarek Abdel-Fatah; Andrew R Green; Graham R Ball; Emad A Rakha; Ian O Ellis; Sudha Sharma; Srinivasan Madhusudan
Journal:  Mol Cancer Ther       Date:  2016-11-11       Impact factor: 6.261

5.  Molecular profiling reveals low- and high-grade forms of primary melanoma.

Authors:  Katja Harbst; Johan Staaf; Martin Lauss; Anna Karlsson; Anna Måsbäck; Iva Johansson; Pär-Ola Bendahl; Johan Vallon-Christersson; Therese Törngren; Henrik Ekedahl; Jürgen Geisler; Mattias Höglund; Markus Höglund; Markus Ringnér; Mattias Ringnér; Lotta Lundgren; Karin Jirström; Håkan Olsson; Christian Ingvar; Åke Borg; Hensin Tsao; Göran Jönsson
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

Review 6.  Targeted therapies in melanoma.

Authors:  Stergios J Moschos; Ramya Pinnamaneni
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

Review 7.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

8.  Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.

Authors:  Nail Fatkhutdinov; Katrin Sproesser; Clemens Krepler; Qin Liu; Patricia A Brafford; Meenhard Herlyn; Katherine M Aird; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2016-06-13       Impact factor: 5.852

9.  Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma.

Authors:  Jianxin Shi; Nilanjan Chatterjee; Melissa Rotunno; Yufei Wang; Angela C Pesatori; Dario Consonni; Peng Li; William Wheeler; Peter Broderick; Marc Henrion; Timothy Eisen; Zhaoming Wang; Wei Chen; Qiong Dong; Demetrius Albanes; Michael Thun; Margaret R Spitz; Pier Alberto Bertazzi; Neil E Caporaso; Stephen J Chanock; Christopher I Amos; Richard S Houlston; Maria Teresa Landi
Journal:  Cancer Discov       Date:  2011-12-07       Impact factor: 39.397

10.  The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.

Authors:  Rosalyn Jewell; Faye Elliott; Jonathan Laye; Jérémie Nsengimana; John Davies; Christy Walker; Caroline Conway; Angana Mitra; Mark Harland; Martin G Cook; Andy Boon; Sarah Storr; Sabreena Safuan; Stewart G Martin; Karin Jirström; Håkan Olsson; Christian Ingvar; Martin Lauss; Tim Bishop; Göran Jönsson; Julia Newton-Bishop
Journal:  Pigment Cell Melanoma Res       Date:  2014-10-01       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.